Dateline City:
WHITEHOUSE STATION, N.J.
Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 percent of patients to date in two of the three combination arms studied
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
announced the presentation of interim data from the ongoing C-WORTHY
Study, a Phase II clinical trial evaluating the efficacy and safety of
an all-oral regimen combining once-daily MK-5172, an investigational
hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an
investigational HCV NS5A replication complex inhibitor, with or without
twice-daily ribavirin, administered for 12 weeks to treatment-nave,
non-cirrhotic pat
Language:
English
Contact:
MerckMedia:Pamela Eisele, (908) 423-5042Sarra Herzog, (908) 423-6154orInvestor:Carol Ferguson, (908) 423-4465Justin Holko, (908) 423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more